In order to address this need for liquid biopsy—including CTC—standardization, several public–private partnerships and consortia were established: BloodPAC, European Liquid Biopsies Academy, Liquid Biopsy Consortium, SPIDIA4P, and the European IMI CANCER-ID consortium currently addressing—among others—the PD-L1 harmonization issue to detect PD-L1+ CTCs in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.